Collectively, the combinatorial therapy with chemotherapy, UPs-4T1/EPB nanovaccine, and STING agonist gives rise to amplified T cell responses with higher diversity and specificity against 4T1/EPB cells, resulting in primary tumor regression and metastasis eradication in most mice, even long-term immune protection from tumor recurrence. Here, STING1 is linked to neoplasm.